Cancer Research Folkman CR Podcast
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marcinkiewicz, C.
Right arrow Articles by Lobb, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marcinkiewicz, C.
Right arrow Articles by Lobb, R. R.
[Cancer Research 63, 2020-2023, May 1, 2003]
© 2003 American Association for Cancer Research

Advances in Brief

Obtustatin

A Potent Selective Inhibitor of {alpha}1ß1 Integrin in Vitro and Angiogenesis in Vivo1

Cezary Marcinkiewicz2, Paul H. Weinreb, Juan J. Calvete, Dariusz G. Kisiel, Shaker A. Mousa, George P. Tuszynski and Roy R. Lobb

Temple University, School of Medicine, Thrombosis Research Center, Philadelphia, Pennsylvania 19140 [C. M., D. G. K., G. P. T.]; Biogen, Inc., Cambridge, Massachusetts 02142 [P. H. W., R. R. L.]; Instituto de Biomedicina, C.S.I.C., 46010 Valencia, Spain [J. J. C.]; and Albany College of Pharmacy and PRI at Albany, Albany, New York 12208 [S. A. M.]


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 
A novel disintegrin, obtustatin, was purified from the venom of the Vipera lebetina obtusa viper. Obtustatin is the shortest disintegrin yet described, containing only 41 amino acids. It contains a similar pattern of cysteines to the short disintegrins echistatin and eristostatin but contains the sequence KTS rather than RGD in its active site loop. Obtustatin is a potent and selective inhibitor of {alpha}1ß1 integrin. It does not inhibit the closely related integrin {alpha}2ß1, nor a panel of other integrins tested. It does not inhibit ligand binding to the recombinant {alpha}1 I-domain. Importantly, obtustatin potently inhibited angiogenesis in vivo in the chicken chorioallantoic membrane assay, and in the Lewis lung syngeneic mouse model, it reduced tumor development by half, confirming and extending previous results on the relevance of {alpha}1ß1 integrin to angiogenesis and suggesting novel approaches to the generation of angiogenesis inhibitors.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results and Discussion
 REFERENCES
 
Angiogenesis, the formation of new vessels, is believed to be central to tumor development and metastasis (1) , and the investigation of suppressors of this process has become a major approach to cancer therapy. At present, many endogenous negative regulators have been identified, including thrombospondin (2) , and a number of proteolytic protein fragments, including angiostatin (3) , endostatin (4) , kininostatin (5) , tumstatin (6) , and arresten (7) . The angiostatic mechanisms of these factors are under intensive investigation, but recent data implicate integrins as potential mediators of these inhibitory processes, e.g., {alpha}5ß1, {alpha}vß3, and {alpha}vß5 integrins are primary targets for endostatin action (8) , whereas angiostatin and tumstatin interact with {alpha}vß3 integrin (6 , 9) . Arresten interacts with the {alpha}1ß1 integrin (7) , which is selective for collagen IV, a major component of basement membranes. These integrins are all expressed on vascular cells, and thus, regulation of vascular cell integrin-ligand interactions is becoming an organizing theme within angiogenesis research.

Disintegrins are the largest group of antiadhesive proteins found in viper venom (10) . The characteristic feature common to all disintegrins is the similar pattern of cysteines and presence of the so-called "integrin-binding" loop. Disintegrins may be divided into two groups, monomeric and dimeric. The monomeric disintegrins form the largest class, usually contain the RGD3 sequence in their integrin-binding loop, and are potent inhibitors of the platelet fibrinogen receptor {alpha}IIbß3 integrin. They have been divided into three subgroups based on the number of cysteines in their molecules (10) . The "short" disintegrins, with only eight cysteines, are represented by the 49 amino acid-containing peptides echistatin and eristostatin, both of which are potent inhibitors of {alpha}IIbß3 integrin. However, only echistatin inhibits other RGD-dependent integrins, such as the vitronectin receptor {alpha}vß3. Here, we describe a novel short monomeric disintegrin called obtustatin. The structure of its integrin-binding loop is novel, and it is a highly selective inhibitor of {alpha}1ß1 integrin in vitro and of angiogenesis in vivo.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results and Discussion
 REFERENCES
 
Cell Lines and Integrins.
K562 cells transfected with {alpha}1 and {alpha}2 integrins were from Dr. P. Gotwals (Biogen, Inc., Cambridge, MA) and Dr. M. Hemler (Dana-Farber Cancer Institute, Boston, MA). The Lewis lung carcinoma cells were from Dr. Bruce Ruggeri (Cephalon, Inc., West Chester, PA). K562 cells were from American Type Culture Collection (Manassas, VA). Collagen type I and IV were from Chemicon International, Inc. (Temecula, CA). Synthetic peptides based on the structure of obtustatin were synthesized commercially by Sigma-Genosis (Woodland, TX).

Purification of Disintegrins.
Obtustatin was purified from the venom of Vipera lebetina obtusa using two steps of reverse phase high-performance liquid chromatography as described (11) . Briefly, 10 mg of Vipera lebetina obtusa venom in 300 µl of 0.1% TFA were injected into C18 column and eluted with an acetonitrile gradient (0–80%) in 0.1% TFA over 45 min at a 2 ml/min flow rate. The obtustatin fraction (1 mg in 500 µl of 0.1% TFA) was reapplied to the same column and eluted with a second acetonitrile gradient (20–80%) over 70 min. The yield of purified obtustatin was 12 mg/grams crude venom. Purity was assessed by SDS-PAGE and matrix-assisted laser desoption ionization-time-of-flight MS using an Applied Biosystems DE-Pro spectrometer (Wistar Institute, University of Pennsylvania, MS facility). Eristostatin was purified from the venom of Eristocophis macmahoni (12) .

Structural Characterization of Obtustatin.
Purified obtustatin was reduced and alkylated as described (11) . S-pyridylethylated obtustatin was characterized by NH2-terminal sequencing (using either an Applied Biosystem 477A or Beckman Porton LF-3000 instrument), amino acid analysis (using a Beckman Gold Amino Acid Analyzer after sample hydrolysis with 6 N HCl, 24 h, 110°C), and MS (as above). The primary structure of obtustatin was deduced from the NH2-terminal sequence analysis of overlapping peptides obtained by endo-Lys C digestion and purified as described (11) .

Cell Adhesion and CFB Assays.
Adhesion studies of cells labeled with 5-(chloromethyl)fluorescein diacetate were performed as described (11) . For the CFB assay (12) , collagen IV- or collagen I-coated Dynabeads M-280 (1 mg/ml) were blocked with 8% Lewis rat plasma in assay buffer [50 mM HEPES (pH 7.5), 150 mM NaCl, and 0.1% Triton X-100] for 5 min. Beads (10 µg) were combined with {alpha}1K562 cell lysate (105 cell equivalents), obtained by lysis of cells with buffer containing 1% NP40 and TS2/16 (0.1 µg/ml) anti-ß1 monoclonal antibody labeled with ruthenium (II) tris-bipyridine N-hydroxysuccinimide ester (IGEN, Inc., Gaithersburg, MD) in assay buffer containing 1 mM MnCl2. In parallel, disintegrins were added. After 1–2-h agitation at room temperature, 200 µl of assay buffer were added, and the samples were read on an ORIGEN electrochemiluminescence detector (IGEN).

Chicken CAM Assay.
The chicken CAM assay was performed as described (5) . Briefly, filter disks were soaked in 3 mg/ml cortisone acetate in solution of 95% ethanol and water and air dried. Disks absorbed with FGF2 (1 µg/ml PBS) in the presence (5 µg/disk) or absence of disintegrins were placed on growing CAMs. At 24 h, disintegrins were added to CAMs topically. After 48 h, the CAM tissue directly beneath FGF2-saturated filter disk was resected from the embryo, and the section was placed in a 35-mm Petri dish and examined under an SV6 stereomicroscope at x50 magnification. Digital images of CAM sections were collected using 3-charge-coupled device camera system (Toshiba) and analyzed with Image-Pro Plus software. The number of vessel branch points contained in a circular region equal to the area of filter disk (angiogenesis index) was counted for each section.

Mouse Model for Tumor Development.
Lewis lung (3) carcinoma cells (1 x 106) were injected under the skin of the C57BL/6 mice (Tacoma, Inc., Germantown, NY). The tumors were allowed to grow for 1 week. The average tumor size at this time, called day 0, was ~0.08 cm3. At day 0, the first i.p. injection of disintegrins was performed. Obtustatin was injected every other day at a dose of 5 mg/kg. In the control group, the PBS was injected with the same frequency. Tumor volume was measured using the standard formula length x width2 x 0.52 (4) . Each group contained four animals.


   Results and Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
REFERENCES
 
Obtustatin was purified to homogeneity from the venom of the Vipera lebetina obtusa viper using two steps of reverse-phase high-performance liquid chromatography. Mass spectroscopy revealed its molecular mass to be 4395.2 Da. The amino acid sequence of obtustatin was established using automated Edman degradation, as applied previously to other disintegrins (11) . This procedure included NH2-terminal sequencing of reduced and pyridylethylated obtustatin and of peptides obtained after degradation with endo-Lys C. The calculated molecular mass of obtustatin is 4394.2 Da, which agrees very well with the mass determined experimentally by matrix-assisted laser desoption ionization MS. Obtustatin, containing only 41 amino acids, is the shortest disintegrin reported to date, with a pattern of cysteines nearly identical to two other short monomeric disintegrins, echistatin and eristostatin, placing it in this subgroup (Fig. 1A)Citation . However, the sequence of its integrin-binding loop is completely different from these other disintegrins, which contain an RGD sequence (Fig. 1A)Citation , suggesting distinct integrin specificity.



View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Structure and activity in vitro of obtustatin. A, amino acid sequence of obtustatin in comparison with two other RGD-containing disintegrins echistatin and eristostatin. The cysteines are underlined, and the functional motifs are in italics. B, effect of obtustatin on adhesion of {alpha}1K562 cells to collagen IV ({bullet}) and {alpha}2K562 cells to collagen I ({circ}). Collagens were immobilized on 96-well plates overnight, and cells were added in the presence or absence of obtustatin in HBSS containing 3 mM Mg2+ and incubated at 37°C for 30 min. The unbound cells were washed away, adhered cells were lysed using 0.5% Triton X-100, and fluorescence was read. C, effect of obtustatin on {alpha}1ß1 integrin binding to collagen IV ({bullet}) and {alpha}2ß1 integrin binding to collagen I ({circ}) in a CFB assay (see "Materials and Methods").

 
Obtustatin was screened against a panel of integrins and found to be a very potent and selective inhibitor of {alpha}1ß1 integrin. It does not inhibit the structurally closely related collagen receptor {alpha}2ß1 integrin (Fig. 1, B and C)Citation . In other cell adhesion assays, obtustatin did not inhibit {alpha}IIbß3 and {alpha}vß3 integrins, four other ß1 integrins ({alpha}4, {alpha}5, {alpha}6, and {alpha}9), or {alpha}4ß7 integrin (data not shown). The anti-{alpha}1ß1 integrin activity of obtustatin was also confirmed in a cell-free assay (Fig. 1C)Citation . Obtustatin inhibited the binding of solubilized {alpha}1ß1 integrin to collagen type IV (0.8 nM IC50) but was without effect in a cell-free assay using solubilized {alpha}2ß1 integrin.

Integrin {alpha}1ß1 contains a so-called "inserted" or I-domain, which is present in the {alpha} subunit, contains ~200 amino acid residues, is localized near the NH2 terminus (13) , is highly conserved, and plays a necessary and direct role in ligand binding. We found that obtustatin did not inhibit the binding of the recombinant {alpha}1 subunit I-domain to collagen IV at concentrations <=1 µM (data not shown). This result suggests that the {alpha}1ß1 integrin may contain a second binding site for collagen IV. It has been found (14) that this integrin may bind two distinct fragments of collagen IV, the pepsin-derived triple helical domain and nonhelical NC1 (noncollagenous) domain. One possibility is that binding of the NC1 fragment does not occur through the I-domain but through another site in common with obtustatin.

A comparison of the integrin-binding loop of obtustatin to related RGD-containing disintegrins (Fig. 1A)Citation suggested that the motif homologous to RGD in obtustatin lies within the sequence KTSLT. The active site of obtustatin was localized by analysis of short peptides. Fig. 2ACitation shows the effects of native obtustatin, EP-obtustatin, and two obtutastin-derived linear synthetic peptides on adhesion of {alpha}1K562 cells to immobilized collagen IV. EP-obtustatin is a refolded form of this protein with reduced S–S bonds and cysteines blocked with vinylpyridine. EP-obtustatin still retained inhibitory activity, but the IC50 increased from 2 nM to 30 µM. The synthetic peptide CWKTSLTSHYS, containing the entire integrin-binding loop, gave an IC50 of 600 µM. In contrast, the peptide CKLKPAGTTC, synthesized based on another part of obtustatin, was not active even at 20 mM. These data indicate that the active site of obtustatin is localized, as expected, within the integrin-binding loop. The essential amino acids for activity within this loop were then localized through alanine scanning (Fig. 2B)Citation . The data revealed that first threonine is critical for activity. The peptides with mutated lysine and serine adjacent to this amino acid lost only partially their inhibitory activity at a 1 mM concentration. These results suggest that the KTS sequence may be a new biologically active motif relevant for the {alpha}1ß1 integrin.



View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Peptide adhesion inhibition of {alpha}1K562 cells to collagen IV. A, inhibitory effect of native obtustatin ({bullet}), EP-obtustatin ({circ}), and two synthetic peptides: CWKTSLTSHYC ({blacktriangleup}) and CKLKPAGTTC ({blacksquare}). B, inhibitory effect of single mutation within synthetic peptides representing the integrin-binding loop of obtustatin. Each peptide contained single conversion of amino acid into alanine. The final concentration of peptides in the adhesion experiment was 1 mM. The activity of each peptide is shown as a bar under the appropriate mutated amino acid.

 
Recent studies suggest that {alpha}1ß1 integrin is important in new vessel development. Vascular basement membrane collagens are proving a rich source of antiangiogenic fragments (6 , 7) . A fragment of the NC1 collagen IV domain, designated arresten, inhibits endothelial cell proliferation in vitro and angiogenesis in vivo, and its mechanism of action is linked to interactions with {alpha}1ß1 integrin (7) . In addition, proteolytic exposure of cryptic sites within collagen type IV, required for angiogenesis and tumor growth in vivo, is associated with the loss of {alpha}1ß1 integrin binding and the gain of {alpha}vß3 integrin binding (15) . Furthermore, {alpha}1 knockout mice show a significant reduction in vascularization of skin tumors, an imbalance in their collagen/collagenase ratios, and circulating angiostatin (16) . In a direct investigation of the mechanisms through which {alpha}1ß1 integrin supports angiogenesis driven by VEGF (17) , it was shown that dermal microvascular EC attachment through {alpha}1ß1 integrin supported robust activation of the Erk1/Erk2 (p44/42) mitogen-activated protein kinase signal transduction pathway driving EC proliferation. Haptotactic EC migration toward collagen I was partially dependent on {alpha}1ß1 integrin, as was VEGF-stimulated chemotaxis of ECs in a uniform collagen matrix. In addition, monoclonal antibody antagonism resulted in ~45% inhibition of VEGF-driven angiogenesis in mouse skin. These studies show a critical role for {alpha}1ß1 integrin in VEGF-driven angiogenesis in the dermis but do not address other agonists or organ compartments. Therefore, to evaluate obtustatin as an angiogenesis inhibitor, we used FGF2, an agonist distinct from VEGF, and an established angiogenesis system not used previously, the chicken CAM. As shown in Fig. 3ACitation , as little as 5 µg of obtustatin potently inhibits FGF2-stimulated new vessel development in the CAM by ~80%. Eristostatin, a disintegrin structurally related to obtustatin (Fig. 1A)Citation but with no integrin receptors expressed on endothelial cells (data not shown), was used as a control and showed no inhibitory activity. Our experiments directly confirm and extend the importance of {alpha}1ß1 integrin in angiogenesis. Moreover, obtustatin significantly inhibited the development of Lewis lung carcinomas in a syngeneic mouse model (Fig. 3B)Citation . On therapeutic treatment of established tumors, obtustatin reduced tumor sizes <=50% after 1 week of treatment. These results agree with genetic studies with {alpha}1-null mice in which tumor growth was also reduced (16) .



View larger version (50K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. In vivo activity of obtustatin. A, effect of obtustatin and eristostatin on angiogenesis in chicken CAM assay. In these experiments, 10-day-old embryos were used, with FGF2 as a growing vessel stimulator. Graphic image of new vessel development under the discs with FGF2. The results of angiogenesis index, counted as a number of vessel branch points: PBS, 60 ± 9; FGF2, 179 ± 23; obtustatin (5 µg), 79 ± 11 (84% inhibition); eristostatin (5 µg), 178 ± 5 (1% inhibition). Each experiment was performed three times. Thus, the mean ± SE is based on 30 separate observations. B, effects of obtustatin ({blacktriangleup}) and PBS ({bullet}) on Lewis lung carcinoma growth in a syngeneic mouse model (n = 4/group; bars represent SE).

 
Additional studies on obtustatin and obtustatin-derived compounds may have a significant impact on development of novel drugs with angiostatic activity. New peptide and peptidomimetic inhibitors have been developed for the therapy of platelet thromboembolism, based on early critical data with RGD/KGD(lysine-glycine-aspartic acid)-containing disintegrin structures (18) . The identification of the novel tri-peptide sequence KTS for {alpha}1ß1 integrin may similarly provide lead compounds for drug development. In addition, although many inhibitors of angiogenesis are known, a detailed understanding of their molecular mechanisms has been lacking. Recent work shows that tumstatin is an endothelial cell-specific inhibitor of protein synthesis, via a novel interaction with {alpha}vß3 integrin (6) . The availability of a well-defined angiogenesis inhibitor of {alpha}1ß1 integrin should also provide insights into the molecular role of this integrin in vascular cell function. Finally, after the discovery of disintegrins in snake venom, a large family of related molecules has been found in mammalian systems, which contain metalloprotease and disintegrin domains, some of which are known to bind integrins (19) . These molecules play critical roles in fertilization, neurogenesis, protein ectodomain shedding, and amyloid precursor protein processing. We suggest that novel mammalian disintegrins may be found, which, like obtustatin, are inhibitors of {alpha}1ß1 integrin and may form a new group of endogenous angiogenesis inhibitors. Interestingly, we note that one member of this family, MDC-9/ADAM-9, does in fact contain the sequence KTS in the disintegrin domain, in a position analogous to that of the obtustatin sequence (20) . We are currently investigating whether MDC-9 binds {alpha}1ß1 integrin.


   ACKNOWLEDGMENTS
 
We thank Dorothy A. Becham for comments on this manuscript and Vicki Rothman for help in animal experiments.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported in part by W. W. Smith Charitable Trust Research Grant (to C. M.), an American Heart Association Beginning Investigator grant (to C. M.), and NIH Grants RO1 CA88931 and R41 CA81822 (both to G. P. T.). Back

2 To whom requests for reprints should be addressed, at Temple University School of Medicine, Thrombosis Research Center, 3400 North Broad Street, Philadelphia PA 19140. E-mail: cmarcink{at}nimbus.temple.edu Back

3 The abbreviations used: RGD, arginine-glycine-aspartic acid; KTS, lysine-threonine-serine; EP, ethylpyridylated; TFA, trifluoroacetic acid; MS, mass spectrometry; CFB, cell-free binding; CAM, chorioallantoic membrane; VEGF, vascular endothelial growth factor; FGF, fibroblast growth factor. Back

Received 1/22/03. Accepted 3/20/03.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 

  1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.[Medline]
  2. Rajstinejad F., Polverini P. J., Buock N. P. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell, 56: 345-355, 1989.[Medline]
  3. O’Reilly M. S., Holmgren L., Shing Y., Chen C., Rosenthal R. A., Moses M., Lane W. S., Cao Y., Sage E. H., Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by Lewis lung carcinoma. Cell, 79: 315-328, 1994.[Medline]
  4. O’Reilly M. S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W. S., Flynn E., Birkhead J. R., Olsen B. R., Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.[Medline]
  5. Colman R. W., Jameson B. A., Lin Y., Johnson D., Mousa S. A. Domain 5 of high molecular weight kininogen (kininostatin) down-regulated endothelial cell proliferation and migration and inhibits angiogenesis. Blood, 95: 543-550, 2000.[Abstract/Free Full Text]
  6. Maeshima Y., Sudhakar A., Lively J. C., Ueki K., Kharbanda S., Kahn R., Sonenberg N., Hynes R. O., Kalluri R. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science (Wash. DC), 295: 140-143, 2002.[Abstract/Free Full Text]
  7. Colorado P. C., Torre A., Kamphaus G., Maeshima Y., Hopfer H., Takahashi K., Volk R., Zambrowsky E. D., Herman S., Sakar P. K., Eriksen M. B., Dhanbal M., Simons M., Post M., Kufe D. W., Weichselbaum R. R., Sukhatme V. P., Kalluri R. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res., 60: 2520-2526, 2000.[Abstract/Free Full Text]
  8. Rehn M., Veikkola T., Kukk-Valdre E., Nakamura H., Ilmonen M., Lombardo C. R., Pihlajaniemi T., Alitalo K., Vouri K. Interaction of endostatin with integrins implicated in angiogenesis. Proc. Natl. Acad. Sci. USA, 98: 1024-1029, 2001.[Abstract/Free Full Text]
  9. Tarui T., Miles L. A., Takada Y. Specific interaction of angiostatin with integrin {alpha}vß3 in endothelial cells. J. Biol. Chem., 276: 562-568, 2001.
  10. Niewiarowski S., McLane M. A., Kloczewiak M., Stewart G. J. Disintegrins and other naturally occurring antagonists of platelet fibrinogen receptors. Semin. Hematol., 31: 289-300, 1994.[Medline]
  11. Marcinkiewicz C., Taooka Y., Yokosaki Y., Calvete J. J., Marcinkiewicz M. M., Lobb R. R., Niewiarowski S., Sheppard D. J. Inhibitory effects of MLDG-containing heterodimeric disintegrins reveal distinct structural requirements for interaction of the integrin {alpha}9ß1 with VCAM-1, tenascin-C and osteopontin. J. Biol. Chem., 275: 31930-31937, 2000.[Abstract/Free Full Text]
  12. Wainreb P. H., Yang W. J., Violette S. M., Couture M., Kimball K., Pepinsky R. B., Lobb R. R., Josiah S. A cell-free electrochemiluminescence assay for measuring b1-integrin-ligand interactions. Anal. Biochem., 306: 305-313, 2002.[Medline]
  13. Leitinger B., Hogg N. Integrin I domains and their function. Biochem. Soc. Transact., 27: 826-832, 1999.[Medline]
  14. Setty S., Kim Y., Fields G. B., Clegg D. O., Wayner E. A., Tsilibary E. C. Interactions of type IV collagen and its domains with human mesangial cells. J. Biol. Chem., 273: 12244-12249, 1998.[Abstract/Free Full Text]
  15. Xu J., Rodriguez D., Petitclerc E., Kim J. J., Hangai M., Yuen S. M., Davis G. E., Brooks P. C. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogensis and tumor growth in vivo. J. Cell Biol., 154: 1069-1080, 2001.[Abstract/Free Full Text]
  16. Pozzi A., Moberg P. E., Miles L. A., Wagner S., Soloway P., Gardner H. A. Elevated matrix metalloprotease and angiostatin levels in integrin {alpha}1 knockout mice cause reduced tumor vascularization. Proc. Natl. Acad. Sci. USA, 97: 2202-2207, 2000.[Abstract/Free Full Text]
  17. Senger D. R., Perruzzi C. A., Streit M., Koteliansky V. E., de Fougerolles A. R., Detmar M. The {alpha}1ß1 and {alpha}2ß1 integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. Am. J. Pathol., 160: 195-204, 2002.[Abstract/Free Full Text]
  18. Bennett J. S. Novel platelet inhibitors. Annu. Rev. Med., 52: 161-184, 2001.[Medline]
  19. Evans J. P. Fertilin beta and other ADAMs as integrin ligands: insights into cell adhesion and fertilization. Bioessays, 23: 628-639, 2001.[Medline]
  20. Weskamp G., Kratzschmar J. R., Reid M., Blobel C. P. MDC-9, a widely expressed cellular disintegrin containing cytoplasmic SH3 ligand domains. J. Cell Biol., 132: 717-726, 1996.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
R. Silva, G. D'Amico, K. M. Hodivala-Dilke, and L. E. Reynolds
Integrins: The Keys to Unlocking Angiogenesis
Arterioscler. Thromb. Vasc. Biol., October 1, 2008; 28(10): 1703 - 1713.
[Abstract] [Full Text] [PDF]

Home page
 MicrobiologyHome page
G. R. Bolduc and L. C. Madoff
The group B streptococcal alpha C protein binds {alpha}1 1-integrin through a novel KTD motif that promotes internalization of GBS within human epithelial cells
Microbiology, December 1, 2007; 153(12): 4039 - 4049.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Sanz, R.-Q. Chen, A. Perez, R. Hilario, P. Juarez, C. Marcinkiewicz, D. Monleon, B. Celda, Y.-L. Xiong, E. Perez-Paya, et al.
cDNA Cloning and Functional Expression of Jerdostatin, a Novel RTS-disintegrin from Trimeresurus jerdonii and a Specific Antagonist of the {alpha}1{beta}1 Integrin
J. Biol. Chem., December 9, 2005; 280(49): 40714 - 40722.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. J. Calzada, D. S. Annis, B. Zeng, C. Marcinkiewicz, B. Banas, J. Lawler, D. F. Mosher, and D. D. Roberts
Identification of Novel {beta}1 Integrin Binding Sites in the Type 1 and Type 2 Repeats of Thrombospondin-1
J. Biol. Chem., October 1, 2004; 279(40): 41734 - 41743.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Monleon, M. P. Moreno-Murciano, H. Kovacs, C. Marcinkiewicz, J. J. Calvete, and B. Celda
Concerted Motions of the Integrin-binding Loop and the C-terminal Tail of the Non-RGD Disintegrin Obtustatin
J. Biol. Chem., November 14, 2003; 278(46): 45570 - 45576.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marcinkiewicz, C.
Right arrow Articles by Lobb, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marcinkiewicz, C.
Right arrow Articles by Lobb, R. R.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online